Holen Sie sich die Stockscreener-App
4.76
2.46%
-0.12
Handel nachbörslich:
4.80
0.04
+0.84%
Schlusskurs vom Vortag:
$4.88
Offen:
$4.87
24-Stunden-Volumen:
46,669
Relative Volume:
0.26
Marktkapitalisierung:
$40.52M
Einnahmen:
$120.77M
Nettoeinkommen (Verlust:
$32.69M
KGV:
1.6332
EPS:
2.9146
Netto-Cashflow:
$-50.94M
1W Leistung:
+0.63%
1M Leistung:
-4.61%
6M Leistung:
-55.72%
1J Leistung:
-34.34%
1-Tages-Spanne:
$4.68
$4.88
1-Wochen-Bereich:
$4.52
$5.16
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.76 | 41.54M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit - lincolnjournal.com
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit - GlobeNewswire Inc.
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - ChartMill
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
ATRA Q1'26 Earnings: EPS estimate is (0.33) USD - TradingView
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, Global Investor Counsel, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
2026-05-03 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
Atara Biotherapeutics Receives Nasdaq Non-Compliance Delisting Notice - TipRanks
Atara Biotherapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Atara Biotherapeutics (NASDAQ: ATRA) faces Nasdaq $50M market value compliance deadline - Stock Titan
ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
ATRA Deadline Alert: The Gross Law Firm Reminds Atara - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Pomerantz LLP Files Investor Lawsuit Against Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ATRA DEADLINE NOTICE: Atara Biotherapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 22, 2026 - ACCESS Newswire
Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Acti - GuruFocus
Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
ATRA Stock Price, Quote & Chart | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Dead - GuruFocus
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Barchart
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
2026-04-28 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Atara Biotherapeutics, - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
2026-04-27 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - Scott Coop
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - WFMZ.com
Atara Biotherapeutics (NASDAQ: ATRA) sets 2026 virtual meeting and equity plan vote - Stock Titan
Lost Money on Atara Biotherapeutics, Inc. (ATRA)? Join - GlobeNewswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
2026-04-23 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):